Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ANNX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 26, 2026 | An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participan… NCT07020819 · Guillain-Barre Syndrome Tanruprubart | ANNX Annexon, Inc. | Phase 3 | Recruiting | 30 | May 31, 2027 | Registry ↗ |
| Oct 21, 2026 | A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With… NCT04656561 · Geographic Atrophy ANX007, Sham comparator | ANNX Annexon, Inc. | Phase 2 | Completed | 270 | Mar 28, 2023 | Registry ↗ |
| Oct 6, 2026 | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Form… NCT06510816 · Geographic Atrophy Vonaprument, Sham Administration | ANNX Annexon, Inc. | Phase 3 | Active, not recruiting | 659 | Jul 31, 2027 | Registry ↗ |
| Sep 8, 2026 | An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With… NCT07807969 · Geographic Atrophy Vonaprument | ANNX Annexon, Inc. | Phase 3 | Not yet recruiting | 605 | Jul 31, 2029 | Registry ↗ |
| Aug 25, 2026 | An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease NCT04514367 · Huntington Disease ANX005 | ANNX Annexon, Inc. | Phase 2 | Completed | 28 | Aug 29, 2022 | Registry ↗ |
| Jun 30, 2026 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Aut… NCT04691570 · Warm Autoimmune Hemolytic Anemia (wAIHA) ANX005 | ANNX Annexon, Inc. | Phase 2 | Completed | 7 | Jan 17, 2023 | Registry ↗ |
| May 29, 2025 | Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome NCT04701164 · Guillain-Barre Syndrome ANX005, Placebo | ANNX Annexon, Inc. | Phase 3 | Completed | 242 | Apr 20, 2024 | Registry ↗ |
| Jan 6, 2025 | Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) NCT04569435 · Amyotrophic Lateral Sclerosis ANX005 | ANNX Annexon, Inc. | Phase 2 | Completed | 17 | Jan 10, 2024 | Registry ↗ |
| Dec 27, 2024 | Dose Study of ANX1502 in Healthy Volunteers NCT05521269 · Healthy ANX1502, Placebo | ANNX Annexon, Inc. | Phase 1 | Completed | 135 | Nov 19, 2024 | Registry ↗ |
| Aug 22, 2024 | A Study of ANX009 in Adult Participants With Lupus Nephritis NCT05780515 · Lupus Nephritis ANX009 | ANNX Annexon, Inc. | Phase 1 | Completed | 7 | Aug 31, 2023 | Registry ↗ |
| Aug 19, 2024 | Single Ascending Dose Study of ANX105 NCT05288881 · Healthy ANX105, Placebo | ANNX Annexon, Inc. | Phase 1 | Completed | 23 | Jun 19, 2023 | Registry ↗ |
| Aug 30, 2021 | A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV) NCT04535752 · Safety and Tolerability in Healthy Volunteers ANX009, Placebo | ANNX Annexon, Inc. | Phase 1 | Completed | 48 | Jun 26, 2021 | Registry ↗ |
| Aug 11, 2021 | A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) NCT04035135 · Guillain-Barré Syndrome ANX005, Intravenous immunoglobulin | ANNX Annexon, Inc. | Phase 1 | Completed | 14 | May 19, 2021 | Registry ↗ |
| Aug 20, 2020 | Study of ANX007 in Participants With Primary Open-angle Glaucoma NCT04188015 · Open Angle Glaucoma 2.5mg ANX007, 5.0mg ANX007 | ANNX Annexon, Inc. | Phase 1 | Completed | 17 | Jun 3, 2019 | Registry ↗ |
| Aug 20, 2020 | Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma NCT03488550 · Open-angle Glaucoma ANX007 | ANNX Annexon, Inc. | Phase 1 | Completed | 9 | Aug 3, 2018 | Registry ↗ |
| Aug 20, 2020 | Single Dose Study of ANX005 in Healthy Volunteers NCT03010046 · Safety and Tolerability in Healthy Volunteers ANX005, IVIg | ANNX Annexon, Inc. | Phase 1 | Terminated | 27 | Jun 2018 | Registry ↗ |
16 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:36 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances